Total: $764.71M | ||||
Company |
Type Of |
Number Of Shares, Units |
Amount Raised (M) | Investors; Placement Agents; Details (Date)@ |
Allon |
Private placement of stock |
6S |
C$6.3 (US$5.3) |
The shares were sold at C$1.05 each; as part of the deal about 2.5M previously issued warrants were redeemed for C$0.05 each (8/29) |
|
|
|
|
|
AMDL Inc. |
Private placement of stock and warrants |
3.164S and 1.9W |
$1 |
The financing had two closings; shares were sold at $0.32 and $0.315 each; the three-year warrants are exercisable at $0.49 and $0.48 per share; Galileo Asset Management SA and Havkit Corp. were placement agents (8/18 and 8/30) |
|
|
|
|
|
Astralis Ltd. |
Private placement of stock and warrants |
18.18S and ND |
$2 |
Blue Cedar Ltd. purchased the shares at $0.11 each; warrant terms were not disclosed; a second closing in the round was expected in September (8/19) |
|
|
|
|
|
Biotech |
Private placement of stock |
0.419S and 0.419W |
C$0.12 (US$0.1) |
A company insider purchased the shares at C$0.29 each; the warrants are exercisable at C$0.39 each (8/10) |
|
|
|
|
|
Boston Life |
Private placement of stock |
6S |
$12.78 |
The shares were sold at $2.13 each; Robert L. Gipson was expected to own 19.9% of the company following the stock sale (8/30) |
|
|
|
|
|
Callisto |
Private placement of stock |
1.87S |
$1.81 |
Existing shareholders purchased the stock at $0.97 per share (8/23) |
|
|
|
|
|
Coley |
Private placement of stock |
0.625S |
$10 |
Pfizer Inc. purchased the shares privately in a deal concurrent with the company's initial public offering; the shares were purchased at the $16 IPO price (8/10) |
|
|
|
|
|
Genta Inc. |
Private placement of stock |
19.1S |
$17.5 |
The shares were sold from an existing registration statement; Piper Jaffray & Co. was placement agent (8/8) |
|
|
|
|
|
GTC |
Private placement of stock and warrants |
4.57S and 1.8W |
$8 |
The shares were sold at $1.75 each; the five-year warrants are exercisable at $2.68 per share; Rodman & Renshaw LLC was placement agent (8/8) |
|
|
|
|
|
Human Genome |
Private placement of convertible notes |
N/A |
$230 |
The 2.25% subordinated notes due 2012 are convertible into common stock at $17.78 per share (8/4) |
|
|
|
|
|
International |
Bought-deal placement of units |
N/A |
C$10 (US$8.4) |
Each unit comprised a $1,000 principal amount 7% convertible debentures and 157 common-share purchase warrants; each four-year warrant is convertible into common stock at $2.85 per share (8/18) |
|
|
|
|
|
Inhibitex Inc. |
Private placement of stock |
5S |
$41.25 |
Institutional investors purchased the shares at $8.25 each; Lazard Capital Markets LLC was placement agent (8/18) |
|
|
|
|
|
InNexus |
Private placement of securities |
N/A |
$3.05 |
The company raised $2.5M through the sale of 8% to 12% notes convertible into 10M shares and 10M $0.25 warrants; it also got a $0.25M bridge loan, and it raised $0.3M through the placement of 1.2M shares and 1.2M $0.30 warrants (8/8) |
|
|
|
|
|
Isis |
Private placement of stock and warrants |
12S and 3W |
$51 |
The shares were sold at $4.25 each, and the warrants are exercisable at $5.23 per share; Needham & Co. and Fortis Securities LLC were placement agents (8/22) |
|
|
|
|
|
Kamada Ltd. |
Initial offering of stock |
1.875S |
NIS30 (US$6.7) |
Kamada completed an initial public offering on the Tel Aviv Stock Exchange; the offering was underwritten by Poalim IBI, Clal Finance Underwriting, Altshouler-Shacham and Rosario Capital (8/17) |
|
|
|
|
|
Large Scale |
Bridge loan |
N/A |
$1 |
Two company officials provided $1M in a term-loan deal, which also included the issuance of warrants; separately, it entered a deal under which it can sell $15M in stock to Brittany Capital over three years (8/8) |
|
|
|
|
|
Manhattan |
Private placement of stock and warrants |
10.76S and 2.15W |
$11.9 |
The shares were sold at $1.11 each; the five-year warrants are exercisable at $1.44 per share; Paramount BioCapital Inc. was placement agent (8/30) |
|
|
|
|
|
MannKind |
Private placement of stock and warrants |
17.1S and 3.4W |
$175 |
Half the money was invested by institutional investors and half by MannKind Chairman and CEO Alfred Mann; the warrants are exercisable at $12.228 per share; Wachovia Securities and Leerink Swann & Co. were placement agents (8/3) |
|
|
|
|
|
Medicure Inc. |
Private placement of stock and warrants |
5.21S and 2.6W |
$3.85 |
The shares were sold at $0.74 each; the five-year warrants are exercisable at $0.97 per share; Satellite Asset Management LP led the placement; Needham & Co. was placement agent (8/22) |
|
|
|
|
|
MIV |
Private placement of securities |
ND |
$4.14 |
Details on the non-brokered private placement were not disclosed (8/22) |
|
|
|
|
|
Nektar |
Private placement of stock and warrants |
1.436S and 0.45W |
$24 |
The shares were sold from a shelf registration at $16.71 to Mainfield Enterprises Inc., which also got a 15-month option to purchase additional shares (8/16) |
|
|
|
|
|
Nutra Pharma |
Private placement of stock and warrants |
24S and 6W |
$9.6 |
SBI Brightline XII LLC is obligated to buy, upon Nutra Pharma's election, up to 24M shares of common stock; the warrants are exercisable from $0.30 to $0.50 per share (8/18) |
|
|
|
|
|
Peplin Ltd. |
Private placement of stock |
11.4S |
A$4 (US$3.1) |
Shares in the placement were sold at A$0.35 each; shareholders also received the right to purchase shares at that price through Aug. 26 (8/2) |
|
|
|
|
|
pSivida Ltd. |
Private placement of stock and warrants |
6.5S and 0.65W |
$4.23 |
The company sold 650,000 American depository receipts at $6.50 each; each ADR represents 10 ordinary shares; the 3-year warrants are exercisable at $12.50 per ADR (8/24) |
|
|
|
|
|
Regeneration |
Private placement of stock |
2.8S |
$23.9 |
The shares were sold at $8.55 each; Pacific Growth Equities LLC was placement agent (8/29) |
|
|
|
|
|
ReNeuron |
Private placement of stock and warrants |
38S and 19W |
£9.5 (US$17.2) |
ReNeuron gained a listing on AIM along with the placement in the UK and U.S.; shares were sold at 25 pence each; the warrants are exercisable at 30 pence each; Collins Stewart and Harris Nesbitt Corp. were agents in the deal (8/5) |
|
|
|
|
|
Rexahn |
Private placement of convertible notes and stock |
N/A and 4.175S |
$9.65 |
The three-year notes are convertible into common stock at $2 per share; the shares were sold at $2 each (8/11) |
|
|
|
|
|
Santarus Inc. |
Private placement of stock |
7.35S |
$31.2 |
The shares were sold from a shelf registration at $4.25 each; SG Cowen & Co. LLC was lead placement agent and RBC Capital Markets Corp. was co-placement agent (8/17) |
|
|
|
|
|
Sonus |
Private placement of stock and warrants |
4.65S and 2.33W |
$16.8 |
Shares were purchased at $3.77 each; for another $0.125 per underlying share, investors also got five-year warrants exercisable at $4.15 per share; investors included Domain Public Equity Partners, Efficacy Capital, MPM BioEquities, ProMed and Heights Capital Management; Punk Ziegel & Co. was placement agent (8/16) |
|
|
|
|
|
Vaso Active |
Private placement of convertible notes and warrants |
N/A and 1.3W |
$2.5 |
The $2.5M in notes due May 2007 are convertible into stock at $0.70 per share; the five- year warrants are exercisable at $0.77 per share; investors also have a right to purchase another $1.88M in notes and 974,026 warrants (8/16) |
|
|
|
|
|
Viventia |
Bridge loans |
N/A |
C$3.3 (US$2.75) |
Viventia Chairman Leslie Dan provided loans totaling C$3.3; they carry a 4.5% annual interest rate (8/12) |
|
|
|
|
|
Vyteris |
Private placement of convertible notes and warrants |
N/A and 2.08W |
$10 |
The three-year, 8% notes are convertible into common stock at $2.40 per share; the warrants are exercisable at $2.88 per share; investors have an option to invest another $5M on those terms (8/19) |
|
|
|
|
|
Xenogen |
Private placement of stock and warrants |
5.155S and 1.55W |
$15 |
The shares were sold at $2.91 each and the warrants are exercisable at $3.29 per share; Thomas Weisel Partners LLC was placement agent (8/11) |
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
AIM = Alternative Market Index; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; TEL = Tel Aviv Stock Exchange; TSE = Toronto Stock Exchange. | ||||
